nach oben

Neurological Sciences

Erschienen in:

17.11.2020 | Original Article

The impact of lymphocytosis and CD4/CD8 ratio on the anti-JCV antibody index and clinical data in patients treated with natalizumab

verfasst von: Jan Kolcava, Monika Hulova, Lucie Rihova, Josef Bednarik, Pavel Stourac

Erschienen in: Neurological Sciences | Ausgabe 7/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Natalizumab is an effective therapy in the treatment of relapsing-remitting multiple sclerosis; it induces lymphocytosis (NIL, natalizumab-induced lymphocytosis) and changes the peripheral lymphocyte pattern.

Methods

This study aims to evaluate NIL, peripheral blood lymphocyte subsets, CD4/CD8 ratio, and their impacts on JCV index and clinical data—No Evidence of Disease Activity (NEDA-3) and annualized relapse rate (ARR) in patients treated with natalizumab.

Results

Forty-one patients (33 women) were included in the study. The mean duration of follow-up on natalizumab treatment was 6.7 ± 3.2 years. Significant increases in relative lymphocytosis after 1 month, with a median of 40.4% (− 34.1 to + 145.5%) (p < 0.001), and after 1 year (49.0% (− 9.3 to + 127.6%)) (p < 0.001) were found. Significant differences were found after 1 month when comparing NIL between patients JCV-seroconverting (20.6% (− 17.7 to 72.7%)) and stable JCV-seronegative ones (43.5% (− 6.3 to +96.3%)) (p = 0.04). No significant difference NIL level was found between the patients exhibiting NEDA-3 status and those without it. ARR on natalizumab treatment correlated with CD4/CD8 ratio (r = 0.356; p = 0.021); patients who maintained NEDA-3 status over the whole treatment period exhibited a lower CD4/CD8 ratio (1.89 ± 1.08 vs. 2.5 ± 0.73; p < 0.04).

Conclusion

This contribution reports the CD4/CD8 ratio as a possible biomarker for better clinical efficacy of natalizumab in patients exhibiting a lower CD4/CD8 ratio. NIL did not correlate with long-term therapeutic efficacy in patients treated with natalizumab, but was demonstrated as lower in patients JCV-seroconverting in the course of follow-up.

Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, Zhang A, Hotermans C, Belachew S, on behalf of the TYSABRI Observational Program (TOP) Investigators (2014) Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry 85:1190–1197. https://doi.org/10.1136/jnnp-2013-306936CrossRefPubMed

Puthenparampil M, Cazzola C, Zywicki S et al (2018) NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis: therapeutic advances in neurological disorders. https://doi.org/10.1177/1756286418805713

Engelhardt B, Kappos L (2008) Natalizumab: targeting α4-integrins in multiple sclerosis. NDD 5:16–22. https://doi.org/10.1159/000109933CrossRef

Camponeschi A, Gerasimcik N, Wang Y, Fredriksson T, Chen D, Farroni C, Thorarinsdottir K, Sjökvist Ottsjö L, Aranburu A, Cardell S, Carsetti R, Gjertsson I, Mårtensson IL, Grimsholm O (2019) Dissecting integrin expression and function on memory B cells in mice and humans in autoimmunity. Front Immunol 10. https://doi.org/10.3389/fimmu.2019.00534

Kim TK, Billard MJ, Wieder ED, McIntyre BW, Komanduri KV (2010) Co-engagement of α4β1 integrin (VLA-4) and CD4 or CD8 is necessary to induce maximal Erk1/2 phosphorylation and cytokine production in human T cells. Hum Immunol 71:23–28. https://doi.org/10.1016/j.humimm.2009.09.360CrossRefPubMedPubMedCentral

Frisullo G, Iorio R, Plantone D, Marti A, Nociti V, Patanella AK, Batocchi AP (2011) CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment. Mult Scler 17:556–566. https://doi.org/10.1177/1352458510392263CrossRefPubMed

Neumann F, Zohren F, Haas R (2009) The role of natalizumab in hematopoietic stem cell mobilization. Expert Opin Biol Ther 9:1099–1106. https://doi.org/10.1517/14712590903055011CrossRefPubMed

Signoriello E, Lanzillo R, Morra VB et al (2015) Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis. Mult Scler J. https://doi.org/10.1177/1352458515604381

Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870–1880. https://doi.org/10.1056/NEJMoa1107829CrossRefPubMed

10.

Ferenczy MW, Marshall LJ, Nelson CDS, Atwood WJ, Nath A, Khalili K, Major EO (2012) Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 25:471–506. https://doi.org/10.1128/CMR.05031-11CrossRefPubMedPubMedCentral

11.

McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P, Nicholas R, Palace J, Pearson OR, Rog D, Young CA (2016) Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 87:117–125. https://doi.org/10.1136/jnnp-2015-311100CrossRefPubMed

12.

Olsson T, Achiron A, Alfredsson L et al (2013) Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler J. https://doi.org/10.1177/1352458513477925

13.

Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9:425–437. https://doi.org/10.1016/S1474-4422(10)70040-5CrossRefPubMedPubMedCentral

14.

Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, Pace A, Cheung A, Chen LL, Berman M, Zein F, Wilson E, Yednock T, Sandrock A, Goelz SE, Subramanyam M (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68:295–303. https://doi.org/10.1002/ana.22128CrossRefPubMed

15.

Aladro Y, Terrero R, Cerezo M, Ginestal R, Ayuso L, Meca-Lallana V, Millán J, Borrego L, Martinez-Ginés M, Rubio L, de Andrés C, Miralles A, Guijarro C, Rodríguez-García E, García-Dominguez JM, Muñoz-Fernández C, López de Silanes C, Gómez M, Thuissard I, Cerdán M, Palmí I, Díaz-Garzón LF, Meca-Lallana J (2016) Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort: JC virus seroprevalence in Spain. J Neurol Sci 365:16–21. https://doi.org/10.1016/j.jns.2016.03.050CrossRefPubMed

16.

Bozic C, Richman S, Plavina T, Natarajan A, Scanlon JV, Subramanyam M, Sandrock A, Bloomgren G (2011) Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 70:742–750. https://doi.org/10.1002/ana.22606CrossRefPubMed

17.

Hegen H, Auer M, Bsteh G, di Pauli F, Plavina T, Walde J, Deisenhammer F, Berger T (2017) Stability and predictive value of anti-JCV antibody index in multiple sclerosis: a 6-year longitudinal study. PLoS One 12:e0174005. https://doi.org/10.1371/journal.pone.0174005CrossRefPubMedPubMedCentral

18.

Kolasa M, Hagman S, Verkkoniemi-Ahola A, Airas L, Koivisto K, Elovaara I (2016) Anti-JC virus seroprevalence in a Finnish MS cohort. Acta Neurol Scand 133:391–397. https://doi.org/10.1111/ane.12475CrossRefPubMed

19.

Kolcava J, Hulova M, Benesova Y, Bednarik J, Stourac P (2019) The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings. Mult Scler Relat Disord 30:187–191. https://doi.org/10.1016/j.msard.2019.02.019CrossRefPubMed

20.

Outteryck O, Zéphir H, Salleron J et al (2013) JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Mult Scler J. https://doi.org/10.1177/1352458513505353

21.

Vennegoor A, van Rossum JA, Leurs C, Wattjes MP, Rispens T, Murk JLAN, Uitdehaag BMJ, Killestein J (2016) High cumulative JC virus seroconversion rate during long-term use of natalizumab. Eur J Neurol 23:1079–1085. https://doi.org/10.1111/ene.12988CrossRefPubMed

22.

Iannetta M, Zingaropoli MA, Bellizzi A, Morreale M, Pontecorvo S, D’Abramo A, Oliva A, Anzivino E, Lo Menzo S, D’Agostino C, Mastroianni CM, Millefiorini E, Pietropaolo V, Francia A, Vullo V, Ciardi MR (2016) Natalizumab affects T-cell phenotype in multiple sclerosis: implications for JCV reactivation. PLoS One 11:e0160277. https://doi.org/10.1371/journal.pone.0160277CrossRefPubMedPubMedCentral

23.

Koudriavtseva T, Sbardella E, Trento E, Bordignon V, D'Agosto G, Cordiali-Fei P (2014) Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab. Clin Exp Immunol 176:320–326. https://doi.org/10.1111/cei.12261CrossRefPubMedPubMedCentral

24.

Stüve O, Marra CM, Jerome KR et al (2006) Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 59:743–747. https://doi.org/10.1002/ana.20858CrossRefPubMed

25.

Warnke C, Stettner M, Lehmensiek V et al (2014) Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. Mult Scler J. https://doi.org/10.1177/1352458514556296

26.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–173. https://doi.org/10.1016/S1474-4422(17)30470-2CrossRefPubMed

27.

Kister I, Kuesters G, Chamot E, Omari M, Dontas K, Yarussi M, Subramanyam M, Herbert J (2014) IV immunoglobulin confounds JC virus antibody serostatus determination. Neurol Neuroimmunol Neuroinflamm 1:e29. https://doi.org/10.1212/NXI.0000000000000029CrossRefPubMedPubMedCentral

28.

Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, Schlain B, Subramanyam M (2013) A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 57:141–146. https://doi.org/10.1016/j.jcv.2013.02.002CrossRefPubMed

29.

Carotenuto A, Scalia G, Ausiello F, Moccia M, Russo CV, Saccà F, de Rosa A, Criscuolo C, del Vecchio L, Brescia Morra V, Lanzillo R (2017) CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients. J Neuroimmunol 309:47–50. https://doi.org/10.1016/j.jneuroim.2017.05.006CrossRefPubMed

30.

Sangalli F, Moiola L, Bucello S, Annovazzi P, Rizzo A, Radaelli M, Vitello G, Grimaldi LME, Ghezzi A, Martinelli V, Comi G (2011) Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. Neurol Sci 31(Suppl 3):299–302. https://doi.org/10.1007/s10072-010-0344-zCrossRefPubMed

31.

Rossi S, Motta C, Studer V, Monteleone F, de Chiara V, Buttari F, Barbieri F, Bernardi G, Battistini L, Cutter G, Stüve O, Salvetti M, Centonze D (2013) A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation. Mult Scler 19:59–68. https://doi.org/10.1177/1352458512448106CrossRefPubMed

Titel: The impact of lymphocytosis and CD4/CD8 ratio on the anti-JCV antibody index and clinical data in patients treated with natalizumab
verfasst von: Jan Kolcava
Monika Hulova
Lucie Rihova
Josef Bednarik
Pavel Stourac
Publikationsdatum: 17.11.2020
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 7/2021
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04897-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

18.04.2024 | Arterielle Hypertonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The impact of lymphocytosis and CD4/CD8 ratio on the anti-JCV antibody index and clinical data in patients treated with natalizumab

Abstract

Background

Methods

Results

Conclusion

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2021

New pharmacological and neuromodulation approaches for impulsive-compulsive behaviors in Parkinson’s disease

Effect of prediabetes on asprin or clopidogrel resistance in patients with recent ischemic stroke/TIA

Skeletal complications in congenital insensitivity to pain and anhidrosis: a problem to reckon with

Constraint-induced movement therapy protocols using the number of repetitions of task practice: a systematic review of feasibility and effects

Type-1 neurofibromatosis mimicking multiple mononeuropathy: the help of nerve ultrasound

The impact of distinct cognitive dual-tasks on gait in Parkinson’s disease and the associations with the clinical features of Parkinson’s disease

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie